Generic Name and Formulations:
Penicillin G potassium 5million Units, 20million Units (IV infusion only); per vial; pwd for IM, IV, intrapleural, intrathecal inj after reconstitution; contains sodium 6.8mg, potassium 65.6mg; per 1million Units.
Indications for PFIZERPEN:
Susceptible severe infections where rapid and high penicillin levels are required (see literature).
Adults and Children:
Bacteremia, pneumonia, endocarditis, pericarditis, empyema, meningitis, other severe infections (due to streptococci, pneumococci, staphylococci): minimum of 5million Units per day. Syphilis: dosage and duration determined by age of patient and stage of disease. Gonorrheal endocarditis: minimum 5million Units per day. Meningococcic meningitis: 1–2million Units IM every 2 hours, or continuous IV drip of 20–30million Units/day. Actinomycosis: 1–6million Units/day for cervicofacial cases; 10–20million Units/day for thoracic and abdominal disease. Clostridial infections: 20million Units/day as adjunctive therapy to antitoxin. Fusospirochetal infections: severe infections of oropharynx, lower respiratory tract, and genital area: 5–10million Units/day. Rat-bite fever: 12–15million Units/day for 3–4 weeks. Listeria infections: Neonates: 500,000–1million Units/day. Adults with meningitis: 15–20million Units/day for 2 weeks. Adults with endocarditis: 15–20million Units/day for 4 weeks. Pasteurella infections: Bacteremia and meningitis: 4–6million Units/day for 2 weeks. Ersipeloid: Endocarditis: 2–20million Units/day for 4–6 weeks. Gram-negative bacillary infections: Bacteremia: 20–80million Units/day. Diphtheria (carrier state): 300,000–400,000 Units/day in divided doses for 10–12 days. Anthrax: a minimum of 5million Units/day in divided doses until cure is effected. See literature re: prophylaxis of bacterial endocarditis in dental procedures.
Cephalosporin, imipenem, or other allergy: not recommended. Asthma. Electrolyte imbalance possible with rapid IV infusion; infuse slowly and monitor electrolytes frequently. Monitor renal, hepatic and hematopoietic function with long-term therapy. Newborns. Infants. Pregnancy (Cat.B). Nursing mothers.
Bacteriostatic antibiotics (eg, erythromycin, tetracycline) may diminish bactericidal effects. Potentiated by probenecid. May cause positive Coombs test.
Rash, drug fever, serum sickness, anaphylaxis, blood dyscrasias, neuropathy, nephropathy, inj site reactions.
Vials (5million Units)—10; 20million Units—1
Clinical Pain Advisor Articles
- FDA Takes Steps to Reconcile Needs of Patients With Chronic Pain, Efforts to Curb Opioid Epidemic
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- Stat Consult: Chronic Low Back Pain
- Opioid Misuse May Help Predict Alcohol Dependence Treatment Outcomes
- Neuropathic Symptoms Worsen Quality of Life, Function in Hip, Knee Osteoarthritis
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- Switching From Buprenorphine-Naltrexone to XR-Naltrexone as Effective as XR-Naltrexone
- History of Migraine May Be Associated With Higher Risk for Cochlear Disorders
- Symptom Severity, Sensory Sensitivity May Indicate Pain Centralization in Chronic Overlapping Pain Conditions
- Human Diagnosis Project Aims to Address Challenges Among Uninsured
- Healthcare Technology Affects Younger Patient Satisfaction
- FDA Announces New Drug Shortages Task Force